T cell therapy called AIC100, which targets the ICAM-1 protein, demonstrated encouraging responses and an acceptable safety ...

Phase-I trial of HSPCAR30 therapy shows 100% response and 50% remission in CD30+ lymphoma patients with no major side effects ...

While CAR-T cell therapies have emerged as a promising alternative for treating B-cell leukemias and lymphomas, their ...

A Phase I trial involving ten patients with relapsed or refractory classical Hodgkin lymphoma or T-cell lymphoma has achieved ...

SunAct Advanced Cancer Therapies expands to Mumbai, offering CAR-T treatments for solid-state tumours, with more centres ...

USC researchers have developed an innovative type of cancer-fighting immune cell, the EchoBack CAR T-cell, that uses focused ...

Researchers from the Sant Pau Research Institute (IR Sant Pau), in collaboration with Sant Pau Hospital and the Josep ...

Researchers in South Korea have proposed a novel cancer immunotherapy approach that could complement existing CAR-T (Chimeric Antigen Receptor T-cell) treatments. Researchers at the Korea Research ...

AML patients in the trial who were treated with SENTI-202 experienced complete remission after not responding to prior ...

The FDA granted breakthrough therapy designation to an autologous CAR-T cell therapy for pediatric patients with diffuse ...

CAR T-cell therapy teaches a person’s immune system how to find and attack their specific cancer But 65% of people haven’t ...